Stoke Therapeutics (STOK) Research & Development (2018 - 2026)

Stoke Therapeutics has reported Research & Development for 9 years, with the latest figure at $39.7 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 21.41% year-over-year to $39.7 million; the trailing twelve-month figure through Mar 2026 stood at $144.9 million (up 45.74% YoY), and the FY2025 full-year result was $137.9 million, up 54.74% from the prior year.
• Research & Development for Q1 2026 stood at $39.7 million, down from $41.7 million in the prior quarter.
• The five-year high for Research & Development was $41.7 million in Q4 2025, with the low at $18.3 million in Q1 2022.
• Average Research & Development over 5 years is $25.1 million, with a median of $21.8 million recorded in 2023.
• Year-over-year, Research & Development surged 84.7% in 2022 and climbed 0.81% in 2023.
• Tracing STOK's Research & Development over 5 years: stood at $21.1 million in 2022, then increased by 3.41% to $21.8 million in 2023, then advanced by 7.55% to $23.4 million in 2024, then surged by 78.01% to $41.7 million in 2025, then decreased by 4.85% to $39.7 million in 2026.
• The last three Research & Development figures came in at $39.7 million (Q1 2026), $41.7 million (Q4 2025), and $37.7 million (Q3 2025), per Business Quant data.

Peer Comparison